Impact of cyclosporine reduction with MMF: A randomized trial in chronic allograft dysfunction. The 'reference' study

American Journal of Transplantation

Volumn 6, Issue 11, 2006, Pages 2725-2734

  Frimat, L ^a   Cassuto Viguier, E ^b   Charpentier, B ^c   Noel C ^d   Provot F ^d   Rostaing, L ^e   Glotz, D ^f   Sraer, J D ^g   Bourbigot, B ^h   Moulin, B ⁱ   Lang, P ^j   Ducloux, D ^k   Pouteil Noble, C ^l   Girardot Seguin, S ^m   Kessler, M ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c BICÊTRE HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f Section of Radiology   (France)

^g HÔPITAL TENON   (France)

^h BREST UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^j HENRI MONDOR HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF BESANÇON   (France)

^l HOSPICES CIVILS DE LYON   (France)

^m Roche   (France)

more..

Author keywords

Chronic allograft nephropathy; Cyclosporine nephrotoxicity; Mycophenolate mofetil; Renal transplant

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; BENIGN TUMOR; BLOOD DISEASE; BRONCHITIS; CHRONIC ALLOGRAFT DYSFUNCTION; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; GASTROINTESTINAL SYMPTOM; GRAFT DYSFUNCTION; GRAFT FAILURE; HERPES SIMPLEX; HUMAN; INFECTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LUNG TUBERCULOSIS; LYMPHATIC SYSTEM DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; VOMITING;

ADULT; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; SAFETY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33750033625     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01535.x     Document Type: Article

References (32)

1. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
2. Merion RM, White DJ, Thiru S, Evans DB, Calne RY. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med 1984; 310: 148-154.
3. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl JMed 2003; 349: 931-940.
4. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
5. Thervet E, Martinez F, Legendre C. Benefit-risk assessment of ciclosporin withdrawal in renal transplant recipients. Drug Saf 2004; 27: 457-476.
6. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39-47.
7. Gonzalez Molina M, Seron D, Garcia del Moral R et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 2004; 77: 215-215.
8. Merville P, Berge F, Deminiere C et al. Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. Am J Transplant 2004; 4: 1769-1775.
9. Vincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282-1287.
10. Flechner SM, Kurian SM, Solez K et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776-1785.
11. Abramowicz D, Del Carmen Rial M, Vitko S et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234-2240.
12. Dudley C, Pohanka E, Riad H et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005; 79: 466-475.
13. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655-662.
14. Pascual M, Curtis J, Delmonico FL et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 2003; 75: 1501-1505.
15. Hueso M, Bover J, Seron D et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998; 66: 1727-1731.
16. Weir MR, Blahut S, Drachenburg C et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24: 379-386.
17. Weir MR, Ward MT, Blahut SA et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567-1573.
18. Hariharan S, Kasiske B, Matas A, Cohen A, Harmon W, Rabb H. Surrogate markers for long-term renal allograft survival. Am J Transplant 2004; 4: 1179-1183.
19. Grinyo JM, Cruzado JM, Millan O et al. Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts. Transplantation 2004; 78: 1400-1403.
20. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-628.
21. Kramer BK, Zulke C, Kammerl MC et al. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant 2003; 3: 982-987.
22. Kasiske BL, Andany MA, Hernandez D, Silkensen J, Rabb H, McClean J, Roel JP, Danielson B. Comparing methods for monitoring serum creatinine to predict late renal allograft failure. Am J Kidney Dis 2001; 38: 1065-1073.
23. Avdonin PV, Cottet-Maire F, Afanasjeva GV, Loktionova SA, Lhote P, Ruegg UT. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 1999; 55: 2407-2414.
24. Saunders RN, Bicknell GR, Nicholson L. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 2003; 75: 772-780.
25. Weir MR, Anderson L, Fink JC et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64: 1706-1710.
26. Morath C, Zeier M. Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells. Int J Clin Pharmacol Ther 2003; 41: 465-469.
27. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 14: 648-654.
28. Dimeny E, Wahlberg J, Lithell H, Fellstrom B. Hyperlipidaemia in renal transplantation-risk factor for long-term graft outcome. Eur J Clin Invest 1995; 25: 574-583.
29. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-590.
30. Schindler R, Tanriver Y, Frei U. Hypertension and allograft nephropathy-cause, consequence, or both? Nephrol Dial Transplant 2000; 15: 8-10.
31. Fellstrom B. Risk factors for and management of post-transplantation cardiovascular disease. Bio Drugs 2001; 15: 261-278.
32. Hesselink DA, van Hest RM, Mathot RA et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005; 5: 987-994.